290 related articles for article (PubMed ID: 15340577)
1. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
[TBL] [Abstract][Full Text] [Related]
3. [Immune response in BALB/c mice immunized with BCG expressing HBV truncated C gene and preS1 gene].
Yin W; Lü X; Lei YF; Yang J; Sun MN; Ma Y; Lan HY; Wang AQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jan; 26(1):28-30. PubMed ID: 20056083
[TBL] [Abstract][Full Text] [Related]
4. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
Li L; Tian YJ; Shen H; Zhao XP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
[TBL] [Abstract][Full Text] [Related]
5. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
Li X; Yang X; Li L; Liu H; Liu J
Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
8. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
Shimizu Y; Guidotti LG; Fowler P; Chisari FV
J Immunol; 1998 Nov; 161(9):4520-9. PubMed ID: 9794377
[TBL] [Abstract][Full Text] [Related]
10. [Immune response in mice induced by the fusion protein of HBcAg and HBV PreS1].
Chen XC; Zhou BP; Li MZ; Wang ZX; Wang HS; Zhang B; Tang W
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):184-5. PubMed ID: 12681075
[No Abstract] [Full Text] [Related]
11. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
12. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
15. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of dendritic cell-based immunization against HBV in transgenic mice.
Jiang WZ; Fan Y; Liu X; Zhang YL; Wen JJ; Hao WL; Qian M
Antiviral Res; 2008 Jan; 77(1):50-5. PubMed ID: 17897731
[TBL] [Abstract][Full Text] [Related]
17. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice.
Yim TJ; Tang S; Andino R
Virology; 1996 Apr; 218(1):61-70. PubMed ID: 8615042
[TBL] [Abstract][Full Text] [Related]
18. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
Bremer CM; Sominskaya I; Skrastina D; Pumpens P; El Wahed AA; Beutling U; Frank R; Fritz HJ; Hunsmann G; Gerlich WH; Glebe D
J Hepatol; 2011 Jul; 55(1):29-37. PubMed ID: 21145866
[TBL] [Abstract][Full Text] [Related]
19. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
20. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response.
Yang BF; Zhao HL; Xue C; Xiong XH; Zhang W; Yao XQ; Liu ZM
Vaccine; 2007 May; 25(22):4478-86. PubMed ID: 17467856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]